Right. There was 20% 3 year survival for treatment vs 8% survival in SOC/placebo including a 3:1 survival benefit to that point for those that crossed over compared to those who did not based on the 2018 numbers with the 2022 unblinded data for treatment patients plugged in. In real numbers that’s 20% of 232 or roughly 47 patients vs 8% of 331 or roughly 27+1 for powering discrepancy from missing 17 SOC/placebo patients, where 6 of those 36 month survivors were crossover patients and 22 were not. By removing the crossover patient benefit noted elsewhere in the data by removing these 6 from the analysis to consider separately you have 22 SOC/placebo vs 47 DCVAX(R)-L treatment living 36 months or more. This is approximately where the long term advantage from DCVAX(R)-L begins per previous analysis by NWBO; ). Best wishes.
Market Data 
Markets 
AI
